Misplaced Pages

Technetium (Tc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of Tc-antibody bound cells. Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis but has not secured FDA approval for use in American markets. In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection. However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.

References

1. "WHO Drug Information" (PDF). Archived from the original (PDF) on 2012-02-19. Retrieved 2009-10-25.
2. Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
3. Skehan SJ, White JF, Evans JW, Parry-Jones DR, Solanki CK, Ballinger JR, et al. (January 2003). "Mechanism of accumulation of 99mTc-sulesomab in inflammation". Journal of Nuclear Medicine. 44 (1): 11–8. PMID 12515870. Archived from the original on 2019-12-10. Retrieved 2019-12-10.
4. EMEA: Summary of product characteristics (LeukoScan) Archived 2006-11-22 at the Wayback Machine
5. Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H (December 2016). "Targeting osteomyelitis with complete besilesomab and fragmented sulesomab antibodies: kinetic evaluations". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 60 (4): 413–23. PMID 25325395.
6. Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J (December 2004). "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine. 29 (12): 781–5. doi:10.1097/00003072-200412000-00001. PMID 15545877. S2CID 46580717.
7. Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
8. Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S (June 2015). "Technetium-99m (mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European Archives of Oto-Rhino-Laryngology. 272 (6): 1377–82. doi:10.1007/s00405-014-2938-1. PMID 24534898. S2CID 25194736.
9. Iyengar KP, Vinjamuri S (June 2005). "Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections". Nuclear Medicine Communications. 26 (6): 489–96. doi:10.1097/00006231-200506000-00003. PMID 15891591. S2CID 41915486.
10. "Products". Immunomedics. Archived from the original on 2019-12-10. Retrieved 2019-12-10.

See also

• Immunoscintigraphy
• Nuclear medicine

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Radiopharmaceuticals
• Technetium-99m
• Antibody-drug conjugates
• Technetium compounds
• Monoclonal antibody stubs